PDE7A and early-onset autosomal dominant Alzheimer disease: Dysregulationof PDE7 has been implicated in neurodegenerative diseases, autoimmunedisorders, chronic inflammation, and metabolic dysfunctions, as elevatedPDE7 activity reduces intracellular cAMP levels, impairing protectivemechanisms that depend on sustained PKA activation.5,6 Consequently,PDE7 inhibitors have emerged as promising therapeutic agents for conditionssuch as multiple sclerosis, Alzheimer’s disease, Parkinson’sdisease, asthma, cognitive impairment, and osteoporosis, aiming torestore cAMP homeostasis and regulate immune responses.